Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy

In order to boost immune responses in persons in whom highly active antiretroviral therapy (HAART) was initiated within 120 days of the onset of symptoms of newly acquired human immunodeficiency virus type 1 (HIV-1) infection, we administered vaccines containing a canarypox virus vector, vCP1452, wi...

Popoln opis

Bibliografske podrobnosti

izdano v:	J Virol
Principais autores:	Jin, Xia, Ramanathan, Jr., Murugappan, Barsoum, Shady, Deschenes, Geoffrey R., Ba, Lei, Binley, James, Schiller, Daryl, Bauer, Daniel E., Chen, Donald C., Hurley, Arlene, Gebuhrer, Lucette, El Habib, Raphaelle, Caudrelier, Pierre, Klein, Michel, Zhang, Linqi, Ho, David D., Markowitz, Martin
Format:	Artigo
Jezik:	Inglês
Izdano:	American Society for Microbiology (ASM) 2002
Teme:	Vaccines and Antiviral Agents
Online dostop:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC135946/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11836398/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/jvi.76.5.2206-2216.2002
Oznake:	Označite Brez oznak, prvi označite!